Related Experiment Videos
Selective activation of anthracycline prodrugs for use in conjunction with ADEPT
D HariKrishna1, A Raghu Ram Rao, D R Krishna
1Department of Medicinal Chemistry, University College of Pharmaceutical Sciences, Kakatiya University, Warangal-506 009, India. dr_krishna@hotmail.com
Abstract:
A major limitation in the chemotherapy of cancer results from the lack of tumor specificity displayed by most anticancer drugs. In this regard, a great deal of research has been focused on the development of new chemotherapeutic agents that are able to effectively exploit the differences between neoplastic and normal tissues. Several cancerous tissues and tumors are rich in certain lysosomal enzymes as compared with those found in the normal tissues. Thus, a prodrug can be designed to selectively target such tumor cells where it can be activated to antineoplastic agent by tumor-associated antigen-targeted monoclonal antibody-enzyme conjugate (antibody directed enzyme prodrug therapy strategy) or by the action of an enzyme present at high levels in tumor tissues (prodrug monotherapy strategy). This approach protects the normal cells from the cytotoxic effects of the drug. In the last few years, a number of new MAb-based reagents has been clinically approved (Rituxan, Herceptin and Panorex), and several others are now in advanced clinical trials. This review focuses on the design of several different enzyme/prodrug combinations with an emphasis on mechanistic insight and clinical activity.
Insights
Targeting cancer with prodrugs enhances chemotherapy specificity. This strategy utilizes tumor-specific enzymes or antibody-directed enzyme prodrug therapy to activate anticancer agents, minimizing damage to healthy cells.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Chemotherapy limitations include lack of tumor specificity, leading to damage in normal tissues.
- Cancerous tissues often exhibit higher levels of specific lysosomal enzymes compared to normal tissues.
Purpose of the Study:
- To review the design of enzyme/prodrug combinations for targeted cancer therapy.
- To explore strategies for activating prodrugs selectively within tumor cells.
Main Methods:
- Prodrug design exploiting tumor-specific enzyme activity.
- Antibody-directed enzyme prodrug therapy (ADEPT) utilizing monoclonal antibodies.
- Review of mechanistic insights and clinical activity of various enzyme/prodrug systems.
Main Results:
- Prodrug activation by tumor-associated enzymes or antibody-enzyme conjugates offers tumor selectivity.
- This approach protects normal tissues from cytotoxic drug effects.
- Several monoclonal antibody-based reagents have received clinical approval or are in advanced trials.
Conclusions:
- Enzyme/prodrug strategies represent a promising approach to improve cancer chemotherapy specificity.
- Targeted activation of prodrugs can enhance therapeutic efficacy while reducing systemic toxicity.